Kestra Medical Technologies (Nasdaq: KMTS) has announced a strategic collaboration with Biobeat Technologies aimed at enhancing diagnostic insights and health monitoring for patients wearing wearable defibrillators. The partnership is particularly designed for patients undergoing cardiac recovery, who require continuous and accurate monitoring of vital signs.
Advanced Monitoring for Wearable Defibrillator Patients
Kestra’s ASSURE® Wearable Cardioverter Defibrillator (WCD) will now be integrated with Biobeat’s FDA-cleared, cuffless blood pressure monitoring technology. This integration allows continuous, non-invasive tracking of blood pressure, heart rate, and other vital signs.
The key benefit is that doctors can monitor patient health in real time, even remotely, enabling timely interventions. This ensures better management of cardiac recovery and reduces the risk of complications.
Investment and Co-Development
Kestra has made an equity investment of approximately $5 million in Biobeat as part of this collaboration. The partnership will allow both companies to combine their expertise and technologies for co-development and commercialisation of enhanced cardiac monitoring solutions.
Kestra’s ACE-PAS study revealed that around 72% of WCD patients experience high blood pressure, highlighting the importance of continuous blood pressure monitoring. With Biobeat’s technology integrated, patient safety and recovery outcomes are expected to improve significantly.
Company Overview
Kestra Medical Technologies
Kestra Medical Technologies is a wearable medical device and digital healthcare company focused on solutions for cardiovascular disease patients.
- Flagship Product: ASSURE® WCD, a wearable device that delivers life-saving defibrillation and continuously monitors patient health.
- Public Listing: Kestra is listed on Nasdaq and recently included in the Russell Indexes, expanding its institutional investor base.
- Mission: To drive innovation in cardiac care through patient-centered wearable solutions.
Biobeat Technologies
Biobeat is a health-tech company specializing in wearable, cuffless, and continuous monitoring devices.
- Their technology allows continuous, non-invasive blood pressure and vital monitoring.
- Doctors can better understand a patient’s cardiovascular profile and make informed decisions.
- Biobeat devices contribute to the growing connected healthcare ecosystem, enabling advanced remote patient monitoring.
Clinical Significance
- The ACE-PAS study shows that 72% of WCD patients experience high blood pressure, a key risk factor during recovery.
- Integration with Biobeat devices enables real-time detection of blood pressure fluctuations and heart events.
- Continuous monitoring allows early interventions, personalized care, and improved recovery outcomes for cardiac patients.
Market Impact and Future Outlook
- This collaboration sets a new benchmark in the wearable cardiac device and digital health space.
- Continuous monitoring and real-time insights provide Kestra and Biobeat a competitive edge in the global cardiac care market.
- By leveraging connected healthcare, AI analytics, and data-driven patient management, modern cardiac care becomes safer, more efficient, and more accessible.
Outcome
The Kestra-Biobeat partnership goes beyond making wearable defibrillators smarter. It represents a significant step toward a safer, data-driven, and patient-focused healthcare ecosystem for cardiac recovery patients.
With this collaboration, patients can experience better recovery, timely medical interventions, and more personalized care, while healthcare providers gain enhanced insights to make informed decisions. The future of wearable cardiac technology is set to become more connected, intelligent, and effective.
Source: globenewswire Kestramedicalnews
:%20Facial%20Rejuvenation%20and%20Modern%20Applications){kind=link}
